That fear might be valid but why would Edding partner and pay $20m? Given the high approval hit rate I would anticipate approval with the price being the key aspect. As long as China negotiates a sufficiently cheap deal, why not take the proven branded option? We passed Chinese regulatory approval in 2024... did the generics in question also attain approval? Didn't the approval come with some exclusivity?
Market Data 
Markets 
AI
